Standout Papers
- Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas (2009)
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer (2018)
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study (2022)
- Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study (2022)
- Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial (2022)
Immediate Impact
6 by Nobel laureates 15 from Science/Nature 83 standout
Citing Papers
Pancreatic cancer
2025 Standout
Natural killer cell therapies
2024 StandoutNature
Works of Philippe A. Cassier being referenced
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.
2023
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Philippe A. Cassier | 3831 | 3092 | 1393 | 286 | 7.1k | |
| Gunhild Mechtersheimer | 2418 | 2335 | 1784 | 191 | 6.5k | |
| Ryoji Kushima | 1926 | 2912 | 1472 | 316 | 6.8k | |
| Didier Cupissol | 4846 | 4338 | 1556 | 160 | 8.7k | |
| Sant P. Chawla | 3829 | 5185 | 1895 | 291 | 9.4k | |
| Antonio Llombart‐Bosch | 1805 | 3305 | 1788 | 292 | 6.5k | |
| Tetsuo Ushiku | 1887 | 1476 | 1484 | 293 | 4.8k | |
| Emmanuelle Bompas | 2560 | 3990 | 761 | 193 | 5.6k | |
| Sophie Piperno‐Neumann | 3407 | 3357 | 1652 | 214 | 6.7k | |
| Scott M. Schuetze | 3261 | 6220 | 1347 | 166 | 8.5k | |
| Scott H. Okuno | 2482 | 3486 | 945 | 177 | 5.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...